Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 6, 2022
Distillery Therapeutics
Targeting three thalamic circuits in Parkinson's disease
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Oct 18, 2021
Regulation
New nasal spray option for dry eye as Oyster Point wins FDA nod
Oyster Point’s Tyrvaya offers dosing advantage over artificial tears
BioCentury | Apr 27, 2020
Product Development
After hitting primary endpoint, Axsome planning second trial in Alzheimer’s agitation
BioCentury | Mar 27, 2020
Emerging Company Profile
Redpin debuts chemogenetic platform for neurology, raises $15.5M
Redpin aims to tamp down neuron excitability with its conditionally active ion channels
BioCentury | Mar 20, 2020
Product Development
Axsome speeds Alzheimer's agitation trial, citing patient vulnerability and FDA guidance
BioCentury | Oct 31, 2019
Financial News
Oyster Point, RAPT post gains after pricing IPOs at low end of range
BioCentury | Oct 16, 2019
Product Development
Relmada data offer hope of safer option for depression
Relmada’s depression therapy may avoid the psychotomimetic effects of J&J’s esketamine, enabling at-home use
BioCentury | Aug 1, 2019
Financial News
Vida seeking bigger deals, cures with $600M fund
With four liquidity events already from its first fund, Vida wants its second to deliver cures
Items per page:
1 - 10 of 50